Status:
COMPLETED
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will assess the effect of LCQ when added to metformin.
Eligibility Criteria
Inclusion
- HbA1c from 7.0-10.0%, Stable Metformin dose
Exclusion
- CHF Class III-IV, Liver disease
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
693 Patients enrolled
Trial Details
Trial ID
NCT00901979
Start Date
April 1 2009
End Date
June 1 2010
Last Update
January 9 2013
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Advantage
Mesa, Arizona, United States
2
Mesa Family Medical Center/Clinical Research Advantage
Mesa, Arizona, United States
3
Woodland International Reserach Group, LLC
Little Rock, Arkansas, United States
4
Associated Pharmaceutical Research
Buena Park, California, United States